What Clinicians Need to Know About Monitoring Lean Mass During Weight Loss
GLP-1 receptor agonists like semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) have transformed the weight loss landscape, helping patients achieve 15 to 20% reductions in body weight. But with prescriptions surging nearly 600% over five years (American Diabetes Association [ADA], n.d.), a critical clinical question has emerged: how much of that weight loss is muscle?
The Hidden Risk: Lean Mass Loss
Research consistently shows that 15 to 40% of total weight lost on GLP-1 therapies may come from lean body mass, including skeletal muscle (Linge et al., 2024; Tinsley et al., 2025). For patients already at risk of sarcopenia, or those in older age groups, this muscle loss can lead to reduced strength, metabolic decline, and increased fall risk (Linge et al., 2024).
In January 2025, a joint advisory from four major medical societies recommended body composition assessment for all patients on GLP-1 therapy (Mozaffarian et al., 2025). The FDA now recommends body composition metrics as clinical endpoints for weight loss treatments (ADA, n.d.). The message is clear: the scale alone is no longer sufficient.
Why Body Composition Monitoring Matters
A standard scale cannot differentiate between fat loss and muscle loss. Two patients with identical weight loss may have vastly different outcomes—one losing primarily fat, the other losing dangerous amounts of lean tissue. Without body composition data, clinicians are operating without a critical piece of the clinical picture (Linge et al., 2024; Mass General Brigham, 2025).
Body composition monitoring during GLP-1 therapy enables clinicians to:
- Track fat loss vs. lean mass loss throughout treatment
- Identify patients at risk of sarcopenia or excessive muscle wasting early
- Adjust exercise and nutrition protocols based on objective, measurable data
- Document outcomes to support evidence-based clinical decisions
- Provide patients with meaningful progress metrics beyond the scale
(American Council on Exercise [ACE], 2025; Mass General Brigham, 2025)
The Solution: Clinical-Grade BIA
Bioelectrical Impedance Analysis (BIA) provides a fast, safe, and non-invasive method to measure body composition—differentiating fat mass, lean tissue, skeletal muscle mass, and body water. Patients build trust in their physicians by tracking their progress with tangible evidence, offering confirmation that their treatment plans are working. By incorporating BIA into a patient treatment plan, physicians have access to precise and reliable data, helping drive better patient outcomes.
How BIA Devices Vary: A Technical Comparison
| Specifications | RJL Quantum V | DEXA Scan | InBody 270S |
|---|---|---|---|
| Investment | $3,490 | $80,000 | $7,855 |
| Scan Time | 13 seconds | 10-20 minutes | 30 seconds |
| Radiation | None | Low-dose X-ray | None |
| Testing Frequency | Unlimited | 4x year (max) | Unlimited |
| Portability | Portable | Dedicated room | Nominally portable |
| Segmental Analysis | 13 segments | Varies by model | 3 frequencies at each of the 5 segments |
Download our Clinical Resource Guide to learn more about integrating body composition monitoring into your practice.
RJL Systems, the inventors of BIA, gives clinicians the most accurate, repeatable body composition data they need to make confident decisions for their patients. Our Quantum V Segmental Analyzer is backed by over 40 years of innovation, 5,000+ scientific studies and the only peer-reviewed DEXA equivalence validation of any BIA device.
Learn more about our devices and give your patients access to gold-standard body composition analysis here:
